N30 Pharma Announces Publication of S-Nitrosoglutathione Reductase Small Molecule Inhibitor Chemistry and Development
BOULDER, CO--(Marketwire - March 14, 2011) -
Highlighted Links |
Article |
Company Website |
The publication can be accessed at: http://pubs.acs.org/journal/amclct
GSNOR breaks down S-nitrosoglutathione (GSNO), and as such is an important regulator of the body's pool of GSNO. In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects. In asthmatics, GSNOR up-regulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy. GSNO has also been found to be important in the gastrointestinal and cardiovascular systems, as well as the regulating the control of breathing. GSNOR inhibitors are novel drug candidates, and represent a new approach to treating asthma and other inflammatory diseases.
Contact Information
Email: Email Contact
Gary J. Rosenthal, PhD
EVP Discovery Research
(720) 945-7712
Charles Scoggin, MD
CEO
(720) 945-7721